Synthesis of Therapeutic Agents for Treatment of Infectious Diseases

用于治疗传染病的治疗剂的合成

• 批准号: 10352180
• 负责人: MARK MIDDLETON
• 金额: $ 125.65万
• 依托单位: STARKS ASSOCIATES, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-16 至 2022-02-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10352180
• 关键词: Acquired Immunodeficiency Syndrome; Animals; Chemicals; Clinical Research; Communicable Diseases; Contractor; Contracts; Diagnosis; Diagnostic; Disease; HIV; Immune; Immunology; In Vitro; Local Microbicides; Mediating; Medical; Microbiology; National Institute of Allergy and Infectious Disease; Phase; Prevention; Regulation; Research; Research Support; Resources; Testing; Therapeutic; Therapeutic Agents; United States Dept. of Health and Human Services; United States National Institutes of Health; infectious disease treatment; microbicide; vaccine development

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of AIDS has a requirement for the synthesis of therapeutics directed against HIV and other infectious diseases as well as agents to serve and anti-HIV topical microbicides. This initiative provides the resources for the synthesis of microbicides and compounds for the treatment of HIV, and other infectious diseases of relevance to the research agenda of NIAID. The contract will synthesize chemicals, in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations if necessary, in quantities needed for testing in in vitro screens, animals, or early Phase I clinical studies.

国家过敏和传染病研究所(NIAID)、国家卫生研究院(NIH)、卫生与公众服务部(DHHS)支持与微生物学和免疫学基本知识有关的研究，从而开发疫苗、治疗学和医学诊断学，以预防、治疗和诊断传染病和免疫介导性疾病。艾滋病研究所艾滋病司要求合成针对艾滋病毒和其他传染病的治疗药物，以及用于和抗艾滋病毒局部杀微生物剂的药剂。这一举措为合成杀微生物剂和化合物提供了资源，用于治疗艾滋病毒和其他与NIAID研究议程相关的传染病。该合同将根据FDA目前的良好制造规范(CGMP)规定(如有必要)合成大量化学品，用于在体外筛查、动物或早期I期临床研究中进行测试。